Synovial Sarcoma - Pipeline Review, H2 2014

Published: Dec, 2014 | Pages: 77 | Publisher: Global Markets Direct
Industry: Healthcare | Report Format: Electronic (PDF)

Synovial Sarcoma - Pipeline Review, H2 2014

Summary

Global Markets Direct's, 'Synovial Sarcoma - Pipeline Review, H2 2014', provides an overview of the Synovial Sarcoma's therapeutic pipeline.

This report provides comprehensive information on the therapeutic development for Synovial Sarcoma, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Synovial Sarcoma and special features on late-stage and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

- The report provides a snapshot of the global therapeutic landscape of Synovial Sarcoma
- The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities 
- The report reviews key players involved in the therapeutics development for Synovial Sarcoma and enlists all their major and minor projects
- The report summarizes all the dormant and discontinued pipeline projects 
- A review of the Synovial Sarcoma products under development by companies and universities/research institutes based on information derived from company and industry-specific sources
- Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- A detailed assessment of monotherapy and combination therapy pipeline projects
- Coverage of the Synovial Sarcoma pipeline on the basis of target, MoA, route of administration and molecule type
- Latest news and deals relating related to pipeline products

Reasons to buy

- Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Develop strategic initiatives by understanding the focus areas of leading companies
- Identify and understand important and diverse types of therapeutics under development for Synovial Sarcoma
- Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline
- Devise corrective measures for pipeline projects by understanding Synovial Sarcoma pipeline depth and focus of Indication therapeutics
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

 Table of Contents
Table of Contents 2
List of Tables 4
List of Figures 4
Introduction 5
Global Markets Direct Report Coverage 5
Synovial Sarcoma Overview 6
Therapeutics Development 7
Pipeline Products for Synovial Sarcoma - Overview 7
Pipeline Products for Synovial Sarcoma - Comparative Analysis 8
Synovial Sarcoma - Therapeutics under Development by Companies 9
Synovial Sarcoma - Therapeutics under Investigation by Universities/Institutes 10
Synovial Sarcoma - Pipeline Products Glance 11
Clinical Stage Products 11
Early Stage Products 12
Unknown Stage Products 13
Synovial Sarcoma - Products under Development by Companies 14
Synovial Sarcoma - Products under Investigation by Universities/Institutes 15
Synovial Sarcoma - Companies Involved in Therapeutics Development 16
Adaptimmune Limited 16
Eisai Co., Ltd. 17
Karyopharm Therapeutics, Inc. 18
Merck & Co., Inc. 19
Novartis AG 20
OncoTherapy Science, Inc. 21
Synovial Sarcoma - Therapeutics Assessment 22
Assessment by Monotherapy Products 22
Assessment by Target 23
Assessment by Mechanism of Action 25
Assessment by Route of Administration 27
Assessment by Molecule Type 29
Drug Profiles 31
Cell Therapy to Target NY-ESO-1 and LAGE-1 for Oncology - Drug Profile 31
Product Description 31
Mechanism of Action 31
R&D Progress 31
Dendritic Cell Therapy to Target MAGE-A1, MAGE-A3, and NY-ESO-1 for Oncology - Drug Profile 33
Product Description 33
Mechanism of Action 33
R&D Progress 33
E-7438 - Drug Profile 34
Product Description 34
Mechanism of Action 34
R&D Progress 34
everolimus - Drug Profile 36
Product Description 36
Mechanism of Action 36
R&D Progress 36
OTSA-101 - Drug Profile 41
Product Description 41
Mechanism of Action 41
R&D Progress 41
pembrolizumab - Drug Profile 42
Product Description 42
Mechanism of Action 42
R&D Progress 42
selinexor - Drug Profile 46
Product Description 46
Mechanism of Action 46
R&D Progress 46
SSTC-104 - Drug Profile 50
Product Description 50
Mechanism of Action 50
R&D Progress 50
Synovial Sarcoma - Recent Pipeline Updates 51
Synovial Sarcoma - Discontinued Products 72
Synovial Sarcoma - Product Development Milestones 73
Featured News & Press Releases 73
Oct 17, 2014: Adaptimmune Announces Interim Results from Pilot Trial of its Engineered NY-ESO T Cells Targeting Synovial Sarcoma 73
Jul 30, 2012: OncoTherapy Science Receives Patent For OTSA101 In Japan And US 75
Oct 16, 2011: OncoTherapy Science's Subsidiary Receives French Approval For Clinical Trial Of OTSA101 75
Appendix 76
Methodology 76
Coverage 76
Secondary Research 76
Primary Research 76
Expert Panel Validation 76
Contact Us 77
Disclaimer 77

List of Tables
Number of Products under Development for Synovial Sarcoma, H2 2014 7
Number of Products under Development for Synovial Sarcoma - Comparative Analysis, H2 2014 8
Number of Products under Development by Companies, H2 2014 9
Number of Products under Investigation by Universities/Institutes, H2 2014 10
Comparative Analysis by Clinical Stage Development, H2 2014 11
Comparative Analysis by Early Stage Development, H2 2014 12
Comparative Analysis by Unknown Stage Development, H2 2014 13
Products under Development by Companies, H2 2014 14
Products under Investigation by Universities/Institutes, H2 2014 15
Synovial Sarcoma - Pipeline by Adaptimmune Limited, H2 2014 16
Synovial Sarcoma - Pipeline by Eisai Co., Ltd., H2 2014 17
Synovial Sarcoma - Pipeline by Karyopharm Therapeutics, Inc., H2 2014 18
Synovial Sarcoma - Pipeline by Merck & Co., Inc., H2 2014 19
Synovial Sarcoma - Pipeline by Novartis AG, H2 2014 20
Synovial Sarcoma - Pipeline by OncoTherapy Science, Inc., H2 2014 21
Assessment by Monotherapy Products, H2 2014 22
Number of Products by Stage and Target, H2 2014 24
Number of Products by Stage and Mechanism of Action, H2 2014 26
Number of Products by Stage and Route of Administration, H2 2014 28
Number of Products by Stage and Molecule Type, H2 2014 30
Synovial Sarcoma Therapeutics - Recent Pipeline Updates, H2 2014 51
Synovial Sarcoma - Discontinued Products, H2 2014 72